Furthermore, SGLT2 inhibitors improve pancreatic β-cell responses to incretin hormones (49), and their preferential administration may affect the regulation of metabolic disorders, prevent complications, and preserve QOL and activities of daily living in patients with T2DM. Here, SLC5A2 is linked to Other metabolic disease.